Evaluation of encapsulated liver cell spheroids in a fluidised-bed bioartificial liver for treatment of ischaemic acute liver failure in pigs in a translational setting

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Selden, Clare ^a   Spearman, Catherine Wendy ^b   Kahn, Delawir ^b   Miller, Malcolm ^b   Figaji, Anthony ^c   Erro, Eloy ^a   Bundy, James ^a   Massie, Isobel ^a   Chalmers, Sherri Ann ^a   Arendse, Hiram ^b   Gautier, Aude ^a   Sharratt, Peter ^d   Fuller, Barry ^a   Hodgson, Humphrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ALPHA 1 ANTITRYPSIN; PROTHROMBIN;

ACIDOSIS; ACUTE LIVER FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BINDING; BIOARTIFICIAL LIVER; BLOOD CLOTTING; CELL ENCAPSULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLUIDIZED BED; HEMODYNAMICS; HEPATIC ARTERY LIGATION; HUMAN; HUMAN CELL; INTRACRANIAL PRESSURE; LIVER CELL; LIVER FUNCTION; NONHUMAN; PH; PROTEIN SYNTHESIS; SPHEROID CELL; TREATMENT RESPONSE;

ANIMALS; BIOREACTORS; CELL SURVIVAL; FEMALE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER FAILURE, ACUTE; LIVER, ARTIFICIAL; SPHEROIDS, CELLULAR; SWINE;

EID: 84893170587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082312     Document Type: Article

References (45)

1. Nyberg SL (2012) Bridging the gap: advances in artificial liver support. Liver Transpl 18 Suppl 2: S10-S14.
2. Rifai K (2011) Fractionated plasma separation and adsorption: current practice and future options. Liver Int 31 Suppl 3: 13-15.
3. Banares R, Nevens F, Larsen F, Jalan R, Albillos A, Dollinger M (2010) Extracorporeal Liver Support with the Molecular Adsorbent Recirculating System (MARS) in Patients with Acute-on-Chronic Liver Failure (AOCLF). The Relief Trial. J Hepatol 52: S459.
4. Carpentier B, Gautier A, Legallais C (2009) Artificial and bioartificial liver devices: present and future. Gut 58: 1690-1702.
5. Roussel JC, Moran CJ, Salvaris EJ, Nandurkar HH, d'Apice AJF, et al. (2008) Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. American Journal of Transplantation 8: 1101-1112.
6. Nibourg GA, Chamuleau RA, van der Hoeven TV, Maas MA, Ruiter AF, et al. (2012) Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. Plos One 7: e38778.
7. Nibourg GA, Chamuleau RA, van Gulik TM, Hoekstra R (2012) Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opin Biol Ther 12: 905-921.
8. Khalil M, Shariat-Panahi A, Tootle R, Ryder T, McCloskey P, et al. (2001) Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. J Hepatol 34: 68-77.
9. Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, et al. (2007) Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol 39: 555-564.
10. Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, et al. (2008) Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnology and Bioengineering 99: 644-651.
11. Selden C, Khalil M, Hodgson H (2000) Three dimensional culture upregulates extracellular matrix protein expression in human liver cell lines - a step towards mimicking the liver in vivo? Int J Artif Organs 23: 774-781.
12. Erro E, Bundy J, Massie I, Chalmers SA, Gautier A, et al. (2013) Bioengineering the liver: scale-up and cool chain delivery of the liver cell biomass for clinical targeting in a bioartificial liver support system. BioResearch Open Access 2: 1-11.
13. David B, Dore E, Jaffrin MY, Legallais C (2004) Mass transfers in a fluidized bed bioreactor using alginate beads for a future bioartificial liver. Int J Artif Organs 27: 284-293.
14. Erro E, Bundy J, Massie I, Gander A, Chalmers SA, et al. (2010) Optimization of the Biomass Growth for the Development of A Clinical Scale Bioartificial Liver Using A Human Derived Cell Line Within Encapsulated Alginate. J Hepatol 52: S322.
15. Erro E, Hodgson H, Selden C (2009) A Clinical Scale Bioreactor for Extracorporeal Bioartificial Liver Machine Using Liver-Derived Human Cells. International Journal Of Artificial Organs 32: 407.
16. Starzl TE, Putnam CW, Groth CG, Corman JL, Taubman J (1975) Alopecia, ascites, and incomplete regeneration after 85 to 90 per cent liver resection. Am J Surg 129: 587-590.
17. Coward SM, Selden C, Mantalaris A, Hodgson HJ (2005) Proliferation rates of HepG2 cells encapsulated in alginate are increased in a microgravity environment compared with static cultures. Artif Organs 29: 152-158.
18. Miyashita T, Enosawa S, Tanaka H, Tamura A, Amemiya H, et al. (2003) Standardization of ischemic hepatic failure in pigs as a model for bioartificial liver assessment. Surg Today 33: 743-750.
19. Nieuwoudt M, Kunnike R, Smuts M, Becker J, Stegmann GF, et al. (2006) Standardization criteria for an ischemic surgical model of acute hepatic failure in pigs. Biomaterials 27: 3836-3845.
20. Spackman DH, Stein WH, Moore S (1958) Automatic Recording Apparatus for Use in the Chromatography of Amino Acids. Anal Chem 30: 1190-1206.
21. Rahman TM, Hodgson HJ (2000) Animal models of acute hepatic failure. Int J Exp Pathol 81: 145-157.
22. Detry O, De RA, Delwaide J, Hans MF, Canivet JL, et al. (2007) Prolonged anhepatic state after early liver graft removal. Hepatogastroenterology 54: 2109-2112.
23. Bode BP, Souba WW (1994) Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells. Ann Surg 220: 411-422.
24. Bode BP, Fuchs BC, Hurley BP, Conroy JL, Suetterlin JE, et al. (2002) Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol 283: G1062-G1073.
25. Martini WZ, Cortez DS, Dubick MA, Park MS, Holcomb JB (2008) Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 65: 535-543.
26. Klein SM, Slaughter TF, Vail PT, Ginsberg B, El Moalem HE, et al. (2000) Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 91: 1091-1095.
27. Tomori T, Hupalo D, Teranishi K, Michaud S, Hammett M, et al. (2010) Evaluation of coagulation stages of hemorrhaged swine: comparison of thromboelastography and rotational elastometry. Blood Coagul Fibrinolysis 21: 20-27.
28. Stange J, Stiffel M, Goetze A, Strube S, Gruenert J, et al. (2011) Industrial stabilizers caprylate and N-acetyltryptophanate reduce the efficacy of albumin in liver patients. Liver Transpl 17: 705-709.
29. Sauer IM, Zeilinger K, Pless G, Kardassis D, Theruvath T, et al. (2003) Extracorporeal liver support based on primary human liver cells and albumin dialysis-treatment of a patient with primary graft non-function. J Hepatol 39: 649-653.
30. Selden C, Shariat A, McCloskey P, Ryder T, Roberts E, et al. (1999) Three-dimensional in vitro cell culture leads to a marked upregulation of cell function in human hepatocyte cell lines-an important tool for the development of a bioartificial liver machine. Annals of the New York Academy of Sciences 875: 353-363.
31. Cai ZH, Shi ZQ, OShea GM, Sun AM (1988) Microencapsulated hepatocytes for bioartificial liver support. Artif Organs 12: 388-393.
32. Chang SJ, Lee CH, Wang YJ (1999) Microcapsules prepared from alginate and a photosensitive poly(L-lysine). J Biomater Sci Polym Ed 10: 531-542.
33. De Vos P, De Haan B, Van Schilfgaarde R (1997) Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials 18: 273-278.
34. Hillebrand DJ, Frederick RT, Williams WW, Brown RS, Napotilano LM, et al. (2010) Safety and Efficacy of the Extracorporeal Liver Assist Device (Elad (R)) in Patients with Acute on Chronic Liver Failure. J Hepatol 52: S323-S324.
35. Wood RP, Katz SM, Ozaki CF, Monsour HP, Gislason GT, et al. (1993) Extracorporeal liver assist device (ELAD): a preliminary report. Transplant Proc 25: 53-54.
36. Stevens AC (2001) An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the HEPATASSIST bioartificial liver support ystem for the treatment of fulminant hepatic failure. Hepatology 34: 299a.
37. Poyck PP, Pless G, Hoekstra R, Roth S, van Wijk AC, et al. (2007) In vitro comparison of two bioartificial liver support systems: MELS CellModule and AMC-BAL. Int J Artif Organs 30: 183-191.
38. Sosef MN, Abrahamse LS, van de Kerkhove MP, Hartman R, Chamuleau RA, et al. (2002) Assessment of the AMC-bioartificial liver in the anhepatic pig. Transplantation 73: 204-209.
39. van de Kerkhove MP, Di Florio E, Scuderi V, Mancini A, Belli A, et al. (2002) Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 25: 950-959.
40. Coward SM, Legallais C, David B, Thomas M, Foo Y, et al. (2009) Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma. Artif Organs 33: 1117-1126.
41. Rahman TM, Selden C, Khalil M, Diakanov I, Hodgson HJ (2004) Alginate-encapsulated human hepatoblastoma cells in an extracorporeal perfusion system improve some systemic parameters of liver failure in a xenogeneic model. Artif Organs 28: 476-482.
42. Erro E, Massie I, Hodgson H, Bundy J, Fuller B, et al. (2011) Oxygen Carriers for Biomass Preservation During the Transport of A Bioartificial Liver. J Hepatol 54: S427.
43. Massie I, Selden C, Hodgson H, Fuller B (2012) Storage Temperatures for Cold-Chain Delivery in Cell Therapy: A Study of Alginate-Encapsulated Liver Cell Spheroids Stored at -80 degrees C or -170 degrees C for Up to 1 Year. Tissue Eng Part C Methods.
44. Massie I, Selden C, Hodgson H, Fuller B (2011) Cryopreservation of encapsulated liver spheroids for a bioartificial liver: reducing latent cryoinjury using an ice nucleating agent. Tissue Eng Part C Methods 17: 765-774.
45. Massie I, Selden C, Morris J, Hodgson H, Fuller B (2011) Cryopreservation of encapsulated liver spheroids using a cryogen-free cooler: high functional recovery using a multi-step cooling profile. Cryo Letters 32: 158-165.